Moreover, if the association of TNNT2 mutations with AF occurrence depends on the underlying mutation-driven pathomechanisms, then tailored preventive treatments for AF can be identified (including Mavacamten and Ranolazine) and tested in selected genotyped HCM subgroups (“R92Q”-like). The gene discussed is TNNT2; the disease is atrial fibrillation.